Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind placebo-controlled study of enzalutamide in advanced hepatocellular carcinoma
2014-004283-37Phase 2Unknown
- Sponsor
- Astellas Pharma
- Start
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hepatocellular carcinoma (HCC) comparing Enzalutamide with Placebo (2 arms). Primary endpoint: Overall survival. Status: unknown.
02
Drugs
enzalutamide
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2014-004283-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004283-37.